6505--Venlafaxine 24HR Sustained Action Capsules

Amendment / Modification

This amendment extends the deadline for the receipt of offers for solicitation 36E79726R0010.

• The hour and date for the receipt of offers is extended.

• The original deadline of March 31, 2026, has been extended to April 2, 2026, at 2:30 PM CT.

• All other terms and conditions of the original solicitation remain unchanged.

Amendment / Modification

This amendment extends the deadline for the receipt of offers for solicitation 36E79726R0010.

• The hour and date for the receipt of offers has been extended.

• The original deadline of March 25, 2026, has been extended to March 31, 2026, at 2:30 PM CT.

• All other terms and conditions of the original solicitation remain unchanged.

Solicitation / RFP / RFQ

This solicitation seeks proposals for the supply of various Venlafaxine HCL capsules in different strengths and package sizes. The contract will establish national contract prices for products distributed through the VA and DoD Pharmaceutical Prime Vendor (PPV) Programs. The estimated annual usage for VA, DoD, IHS, and BOP facilities is detailed in the Schedule of Supplies.

• Products: Venlafaxine HCL capsules in 37.5MG, 75MG, and 150MG strengths.

• Packaging: Unit of use bottles (30, 90 count) and bulk bottles (500, 1000 count). Unit of use bottles require specific safety caps, minimum 120cc volume, cylindrical body, 5.75" circumference, and a 5.25" x 2" label space.

• Compliance: Products must meet FDA requirements, including approved NDAs/ANDAs/BLAs. Manufacturing facilities must have acceptable cGMP status with the FDA. Bar code labeling (GS1-128 or HIBCC HIBC) is required on unit-of-use packaging.

• DSCSA: Compliance with Drug Supply Chain Security Act (DSCSA) requirements, including serialized DSCSA Transaction Information and Transaction Statements using GS1 EPCIS files.

• Letter of Commitment: Required from manufacturers for non-manufacturer offerors.

• Contract Type: Firm Fixed Price, Indefinite-Delivery Requirements contract.

• Period of Performance: Implementation Period (max 60 days) plus a one-year Ordering Period, with four one-year option periods.

• Distribution: Products will be distributed through Government Prime Vendor (PPV) contracts (McKesson, Cencora, Cardinal Health, DMS Pharmaceutical Group).

• Payment: Contractors will receive payments from PPVs, not directly from the Government. No invoices will be provided to Government ordering facilities.

• Submission: Proposals must be submitted via email to Andrew.cazares@va.gov and Nicholas.McGregor@va.gov as Microsoft Word or PDF files, including a scanned SF-1449. Faxed proposals are not acceptable. Zip files are rejected.

• Pricing: Offerors must submit prices for all line items for the base year and all four option years. Prices must include a 0.50% Cost Recovery Fee.

• Evaluation: Award will be made to the responsible offeror with the lowest price technically acceptable offer. Technical acceptability includes meeting product descriptions, unique NDC numbers, FDA approval, and FDA cGMP compliance for manufacturing facilities.

• Deadline: Offerors must hold prices firm for 120 calendar days from the receipt date.

• Subcontracting Plan: Required for other than small business concerns for contracts over $900,000.

• SAM Registration: Offerors must maintain current and accurate registration in the System for Award Management (SAM).

• Manufacturer Requirements: Offerors not manufacturing the items must submit a Letter of Commitment from the manufacturer.

• The document references several attachments (A, B, C, D) for PPV contractor details, estimated requirements, and subcontracting plan templates.

• Offerors must provide their own unique 11-digit NDC number, including their own labeler code.

• A 0.50% Cost Recovery Fee is embedded in all offered prices and must be reported quarterly.

Solicitation / RFP / RFQ

This is a pre-solicitation notice for an unrestricted procurement of Venlafaxine Hydrochloride (HCL) 24-Hour (24HR) Sustained Action (SA) Capsules. The Department of Veterans Affairs (VA) National Acquisition Center intends to issue a Request for Proposal (RFP) for an uninterrupted supply of these capsules to the VA (including CMOPs and State Veterans Homes), Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC).

• The contract will be for Venlafaxine HCL 24HR SA Capsules in various strengths and package sizes.

• Offerors must state the exact name of the drug as it appears on the label and possess a unique NDC number for their product.

• The successful offeror's label with its unique NDC will be the only label permitted on the product.

• Unit of use packaging for specific line items (1, 2, 4, 5, 7, and 8 - 30 and 90 count bottles) must include a safety-cap (deshellable or convertible to non-safety) and a bottle with a minimum 120cc volume, cylindrical body, minimum 5.75" circumference, and a label area of 5.25" x 2" to accommodate barcodes and expiration dates.

• The contract will be awarded to a responsible offeror providing an uninterrupted source of supply.

• The contract period will be one year with four pre-priced one-year option periods.

• Contract items will be distributed through the VA’s and DoD’s respective Pharmaceutical Prime Vendor Programs.

• The solicitation (RFP # 36E79726R0010) will be issued electronically in accordance with FAR Part 12 on or about February 17, 2026.

• The tentative closing date for proposals is March 3, 2026.

• Interested offerors should continuously monitor SAM.gov for amendments and documents.

• All responsible sources may submit an offer.

• This procurement is unrestricted.

• NAICS Code: 325412

• Contracting Office Address: Department Of Veterans Affairs, OPAL/National Contracting Office, Building 37, 1st Avenue, One Block North of Cermak, Hines, IL 60141.

• Point of Contact: Andrew Cazares, Contract Specialist, andrew.cazares@va.gov, (708)786-4990.

• Estimated annual requirements for various Venlafaxine HCL strengths and package sizes are detailed in the document.